Why the study?
Percutaneous coronary intervention strategies remain debated in patients with high bleeding risk.
Does paclitaxel-coated balloon reduce late luminal loss and restenosis compared to bare-metal stent in high bleeding risk patients with de novo coronary lesions?
Does paclitaxel-coated balloon reduce late luminal loss and restenosis compared to bare-metal stent in high bleeding risk patients with de novo coronary lesions?
In high bleeding risk patients with de novo coronary lesions, FFR-guided paclitaxel-coated balloon treatment with 1 month of DAPT significantly reduced late luminal loss and restenosis at 9 months compared to bare-metal stents.
No takes yet. Share an insight, caveat, or question.
PCB may be feasible for high-bleeding-risk PCI; leaves open randomized confirmation of 9-month angiographic and physiologic outcomes.
Shin et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: